On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Q1 Production’s 6th Annual Pharmaceutical & Biotech Medical Affairs Pre-Launch Strategies Conference

Date: June 16-18, 2021
Virtual Event
Event Highlights

  • The virtual event aims to promote the attainment of pre-launch excellence in strategic cross-functional alignment by optimizing publication strategies and supporting product approvals
  • The three-day event adopts a half-day format to maximize retention and engagement
  • It will feature two 15-minute networking and coffee breaks daily, complemented by a virtual platform that supports an array of networking features beyond the capabilities of a Zoom meeting
  • The event will take a broad educational approach in which 25+ facilitators will provide industry insights through case studies, presentations, Q&A sessions, and panel discussions

The 6th Annual Pharmaceutical & Biotech Medical Affairs Pre-Launch Strategies Conference, a three-day virtual event to be held June 16-18, 2021, focuses on achieving pre-launch excellence in strategic cross-functional alignment by optimizing publication strategies and supporting, at an evidentiary level, the approval of products.

Organized by Q1 Production, the event will take an educational approach, comprising case studies, panel discussions, Q&A sessions, and presentations, and feature a half-day format for the three days to maximize engagement and retention. Further, it will be held on the Q1 Productions virtual event app that enhances both collaboration and networking.

As a three-day event, the agenda is divided into three modules, each representing a day’s program. The event will kick off with a presentation on the Innovative approaches for enhanced HCP engagement, of course, after the opening remarks from Q1 Productions. A second presentation will follow 45 minutes later in which Brant Jarrett, PhD, Executive Director, Head of Field Medical Affairs at Mallinckrodt Pharmaceuticals (OTC: MNKKQ), will explore how to shape new pre-launch processes following the disruption caused by the COVID-19 pandemic. A 15-minute coffee and networking break will follow.

Day one will continue in earnest thereafter, with a video chat featuring a panel of three facilitators, followed by three other presentations. In all, the first day will feature nine speakers drawn from various companies that deal with pharmaceuticals, biotechnology, and medical affairs.

Module 2 will begin with a two-part session series titled Practical approach to investigator-initiated trial integration into the medical strategy; the second part will be a panel discussion. In total, day two will feature two panel discussions and three presentations by ten speakers holding senior positions in at companies like Taiho Oncology, Mallinckrodt Pharmaceuticals, Daiichi Sankyo (TYO: 4568), Alkermes PLC (NASDAQ: ALKS), Coherus Biosciences Inc (NASDAQ: CHRS), and more.

Day three’s program will include presentations and panel discussions from seven speakers, who will explore the following topics: natural language processing, product differentiation in highly competitive markets, partnering to maximize data relevance and payer adoption, and, lastly, collaborating with the patient advocacy department to expose gaps in medical strategies.

Q1 Productions, an event organizer leveraging more than 15 years’ experience to deliver educational programming across job functions and industries through curated events, understands attendees’ needs. In this regard, Q1 has facilitated the customization of attendees’ experiences and provided an opportunity for them to get answers to their unique concerns by integrating Q&A sessions into the program, particularly after every presentation or panel discussion.

Furthermore, there will be two 15-minute networking and coffee breaks daily. These breaks, coupled with the features on its virtual platform that promote collaboration, are bound to make the conference an interactive and fun experience for everyone in attendance.

Attendees should expect to learn about the blueprints that ensure the objectives of R&D and commercial teams remain cardinally aligned to the goals of an organization and how their peers ethically distribute scientific information about products to stakeholders. In sum, this curated conference is exquisitely loaded with a mixed bag of informative and networking sessions ideal for players in the medical affairs and medical science liaison professions.

For more information regarding the event, visit https://nnw.fm/9f8vP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217